News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lee Pharmaceuticals (LPHM) Subsidiary In-Licenses Dyax Corp. (DYAX) Drug for China Market


2/11/2013 10:50:53 AM

by Richard Daverman, PhD

February 8, 2013 -- CVie Therapeutics, a subsidiary of Hong Kong-based Lee's Pharma, has in-licensed China rights to Kalbitor®, a treatment for hereditary angioedema, from Dyax Corp. of the US. CVie will be responsible for securing regulatory approval of the drug in China. It has been available in the US since 2010. Lee’s markets western drugs for sale in mainland China; it also has an in-house R&D drug development operation. More details....

Stock Symbols: (HK: 00950) (NSDQ: DYAX)


Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES